Valerio Mammoli1, Alessandro Bonifazi1,2, Diego Dal Ben1, Mario Giannella1, Gianfabio Giorgioni1, Alessandro Piergentili1, Maria Pigini1, Wilma Quaglia1, Ajiroghene Thomas1, Amy H Newman2, Sergi Ferré3, Marta Sanchez-Soto3, Thomas M Keck2,4, Fabio Del Bello5. 1. School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy. 2. Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA. 3. Integrative Neurobiology Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA. 4. Department of Chemistry & Biochemistry, Department of Biomedical & Translational Sciences, College of Science and Mathematics, Rowan University, 201 Mullica Hill Road, Glassboro, NJ, 08028, USA. 5. School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy. fabio.delbello@unicam.it.
Abstract
Over the years, the 2-substituted imidazoline nucleus has been demonstrated to be a bioversatile structural motif. In this study, novel imidazoline derivatives bearing a 3- and/or 4-hydroxy- or methoxy-substituted phenyl ring, linked by an ethylene bridge to position 2 of an N-benzyl- or N-phenethyl-substituted imidazoline nucleus, were prepared and studied against D2 -like receptor subtypes. Binding studies highlighted that a set of N-phenethylimidazoline compounds are selective for D4 over D2 and D3 receptors. In functional assays, the 3-methoxy-substituted derivative, endowed with the highest D4 affinity value, and its 3-hydroxy analogue behaved as partial agonists with low intrinsic efficacy and as competitive D4 antagonists when tested in the presence of the D2 -like receptor agonist quinpirole. Molecular docking analysis, performed using a homology model of the human D4 receptor developed using the X-ray crystal structure of the antagonist-bound human D3 receptor as a template, was in accordance with the binding results and provided useful information for the design of novel imidazoline D4 receptor ligands based on this new scaffold.
Over the years, the 2-substituted imidazolinenucleus has been demonstrated to be a bioversatile structural motif. In this study, novel n class="Chemical">imidazoline derivatives bearing a 3- and/or 4-hydroxy- or methoxy-substituted phenyl ring, linked by an ethylene bridge to position 2 of an N-benzyl- or N-phenethyl-substituted imidazoline nucleus, were prepared and studied against D2 -like receptor subtypes. Binding studies highlighted that a set of N-phenethylimidazoline compounds are selective for D4 over D2 and D3 receptors. In functional assays, the 3-methoxy-substituted derivative, endowed with the highest D4 affinity value, and its 3-hydroxy analogue behaved as partial agonists with low intrinsic efficacy and as competitive D4 antagonists when tested in the presence of the D2 -like receptor agonist quinpirole. Molecular docking analysis, performed using a homology model of the humanD4 receptor developed using the X-ray crystal structure of the antagonist-bound human D3 receptor as a template, was in accordance with the binding results and provided useful information for the design of novel imidazolineD4 receptor ligands based on this new scaffold.
Authors: Meena V Patel; Teodozyj Kolasa; Kathleen Mortell; Mark A Matulenko; Ahmed A Hakeem; Jeffrey J Rohde; Sherry L Nelson; Marlon D Cowart; Masaki Nakane; Loan N Miller; Marie E Uchic; Marc A Terranova; Odile F El-Kouhen; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Renjie Chang; Brenda R Martino; Jill M Wetter; Kennan C Marsh; Ruth Martin; John F Darbyshire; Gary Gintant; Gin C Hsieh; Robert B Moreland; James P Sullivan; Jorge D Brioni; Andrew O Stewart Journal: J Med Chem Date: 2006-12-14 Impact factor: 7.446
Authors: Pooja Sood; Nagi F Idris; Susan Cole; Ben Grayson; Joanna C Neill; Andrew M J Young Journal: J Psychopharmacol Date: 2010-11-18 Impact factor: 4.153
Authors: P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross Journal: CNS Neurol Disord Drug Targets Date: 2006-02 Impact factor: 4.388
Authors: Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson Journal: J Comput Chem Date: 2009-12 Impact factor: 3.376